TY - JOUR
T1 - Eosinophilic pustular folliculitis (Ofuji's disease)
T2 - Indomethacin as a first choice of treatment
AU - Ota, T.
AU - Hata, Y.
AU - Tanikawa, A.
AU - Amagai, M.
AU - Tanaka, M.
AU - Nishikawa, T.
PY - 2001
Y1 - 2001
N2 - Eosinophilic pustular folliculitis (EPF) is characterized by erythematous patches of large follicular papules and pustules involving mainly the face. Although various treatments have been attempted for EPF, including systemic and topical steroid, diaphenylsulphone, colchicine, minocycline as well as UVB phototherapy, there is no consensus on the first choice of treatment. We report a typical case and summarize 25 patients with EPF treated in our hospital between 1978 and 1998. Indomethacin was most frequently used (12/25) and showed clinical improvement in the majority of the cases (11/12). The effect of indomethacin was usually observed within 1-2 weeks after initiation of treatment. Decrease of peripheral blood eosinophils accompanied the clinical improvement. Thus, indomethacin should be considered as a first choice of treatment for EPF.
AB - Eosinophilic pustular folliculitis (EPF) is characterized by erythematous patches of large follicular papules and pustules involving mainly the face. Although various treatments have been attempted for EPF, including systemic and topical steroid, diaphenylsulphone, colchicine, minocycline as well as UVB phototherapy, there is no consensus on the first choice of treatment. We report a typical case and summarize 25 patients with EPF treated in our hospital between 1978 and 1998. Indomethacin was most frequently used (12/25) and showed clinical improvement in the majority of the cases (11/12). The effect of indomethacin was usually observed within 1-2 weeks after initiation of treatment. Decrease of peripheral blood eosinophils accompanied the clinical improvement. Thus, indomethacin should be considered as a first choice of treatment for EPF.
UR - http://www.scopus.com/inward/record.url?scp=0035056868&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035056868&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2230.2001.00790.x
DO - 10.1046/j.1365-2230.2001.00790.x
M3 - Article
C2 - 11298111
AN - SCOPUS:0035056868
SN - 0307-6938
VL - 26
SP - 179
EP - 181
JO - Clinical and Experimental Dermatology
JF - Clinical and Experimental Dermatology
IS - 2
ER -